Sarepta Therapeutics
SRPT
$118.59
Share price
-2.17%
Change (1 day)
23.39%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
Sarepta Therapeutics (SRPT) - Total debt
Total debt on the balance sheet as of June 2023 : $1.36 B
According to Sarepta Therapeutics 's latest financial reports the company's total debt is $1.36 B. A company’s total debt is the sum of all current and non-current debts.
Sarepta Therapeutics - Total debt on balance sheet (from 2007 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $1.61 B | 42.07% |
| 2021-12-31 | $1.13 B | 6.11% |
| 2020-12-31 | $1.07 B | 47.04% |
| 2019-12-31 | $0.72 B | 73.49% |
| 2018-12-31 | $0.42 B | -2.44% |
| 2017-12-31 | $0.43 B | 2569.05% |
| 2016-12-31 | $16.15 M | -30.98% |
| 2015-12-31 | $23.39 M | 269.75% |
| 2014-12-31 | $6.32 M | 279.38% |
| 2013-12-31 | $1.66 M | -5.07% |
| 2012-12-31 | $1.75 M | -4.61% |
| 2011-12-31 | $1.84 M | -4.21% |
| 2010-12-31 | $1.92 M | -3.9% |
| 2009-12-31 | $2 M | -3.55% |
| 2008-12-31 | $2.07 M | -3.13% |
| 2007-12-31 | $2.14 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $25.23 B | 1,749.43% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | $0.70 B | -48.51% | 🇺🇸 USA |
 Novavax NVAX | $0.19 B | -85.42% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | $1.31 B | -3.69% | 🇺🇸 USA |
 Insmed INSM | $1.18 B | -12.97% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | $0.75 B | -44.65% | 🇺🇸 USA |
 Avidity Biosciences RNA | $9.51 M | -99.30% | 🇺🇸 USA |